AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

VENCLEXTA in combination with LDAC did not significantly improve OS versus placebo in combination with LDAC. The HR for OS was 0.75 (95% CI: 0.52, 1.07); p-value 0.114.

VENCLEXTA/VENCLYXTO is approved in more than 50 countries, including the U.S. Uses and Important VENCLEXTA® (venetoclax) U.S. Safety Information7 UsesVENCLEXTA is a prescription medicine used: ...

Following, all patients completed 12 cycles of IMBRUVICA plus VENCLEXTA/VENCLYXTO combination regimen. MRD status was evaluated in PB after 6, 9, and 12 cycles and in BM after 12 cycles of ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

Venclexta, a first-in-class BCL2 inhibitor, is currently approved in combination with rituximab for the treatment of patients with CLL or small lymphocytic lymphoma (SLL), with or without 17p ...

Venclexta is synergistic with Imbruvica in chronic lymphocytic leukemia (ASCO June 3, 2018). Allayed therefore should be any concern that Imbruvica's estimated 70% market share of second line CLL ...

AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

The proportion of patients who had uMRD in PB increased over time from 57 percent after 6 cycles, 68 percent after 9 cycles, and 73 percent after 12 cycles of IMBRUVICA plus VENCLEXTA/VENCLYXTO.